A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors

J Randolph Hecht,Steven Raman,Daniel Y Sze,A Craig Lockhart,Rebecca A Moss,Kate Liu,Jeffrey Chou,Tony Reid

Journal for ImmunoTherapy of Cancer（2015）

Cited 4|Views11

No score

Abstract

Meeting abstracts T-VEC, an intralesionally-delivered oncolytic immunotherapy, is a herpes simplex virus-1 engineered to selectively replicate in tumors and stimulate an anti-tumor immune response through expression of GM-CSF. T-VEC has the ability to lyse various cancer cell types in vitro[[1][1

Translated text

Key words

Liver Tumor, Maximum Tolerate Dose, Compute Tomography Guidance, Dose Cohort, Metastatic Liver Tumor

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined